Corporate reputation is at times mistakenly viewed as a soft asset, yet it holds clear bottom-line consequences. Following our rules for reputation can make the difference between a physician writing a script for your treatment — or not.

WE’s 2024 Brands in Motion health report, “Reputation Rules: Unlocking Physician Prescribing Power,” validates and builds on our survey findings from last year of a wider group of healthcare practitioners, which first revealed the direct connection between corporate reputation and prescribing decisions.

WHAT WE FOUND

  • Reputation matters to physicians. A company’s leadership in a specific disease area, as well as its overall corporate reputation, tops the list of factors most likely to shape physicians’ prescribing decisions in 2024.
  • Reputation needs to be built at different tiers. Having an above-brand, disease-specific reputation will allow a company to speak beyond specific medicines and tell a more holistic story of its commitment to a therapeutic area.
  • Physicians prefer brands that instill confidence in product quality and efficacy. Brand-building narratives should emphasize evidence-based outcomes, quality control and transparency about clinical trials.
  • Physicians also tend to trust brands that place patients first. Most of them believe that the most important aspect of innovation is a commitment to addressing unmet medical needs through patient-centric solutions.

 

REPUTATION RULES FOR BIOPHARMA BRANDS

 

Lead with innovation

Highlight both the scientific and patient journey from molecule to medicine.

 

Treat physicians as partners

Companies must be transparent around pricing structures and access programs to win physicians over.

 

Capitalize on digital trends

Social media continues to rise as an important information channel.

Contact Us

talktoWE@we-worldwide.com

Legacy Brands in Motion

Let Brands in Motion be your north star.

Connect with WE